Welldoc said that its combination of real-time continuous glucose monitoring (CGM) and digital health impacts glucose control in type 2 diabetes. Columbia, Maryland-based Welldoc presented data at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from a study of real-time CGM and digital health in individuals with type 2 diabetes not treated with […]
Dexcom
Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit
Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare. San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit. According to a news release, effective mid-April 2022, members with diabetes will be eligible […]
Dexcom launches Dexcom One CGM in the UK
Dexcom (NSDQ:DXCM) announced today that it launched the new Dexcom One continuous glucose monitoring (CGM) system in the United Kingdom. San Diego-based Dexcom designed the Dexcom One system as an easy-to-use, real-time CGM (rt-CGM) that it aims to make more affordable and accessible for people with diabetes in the UK. According to a news release, […]
Analysts say high payor coverage, increased CGM adoption bodes well for Abbott, Dexcom
Analysts have suggested that companies like Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in […]
Dexcom’s board approves 4-for-1 forward stock split
Dexcom (Nasdaq:DXCM) announced today that its board of directors approved a four-for-one forward split of the company’s common stock. San Diego-based Dexcom’s stock split remains contingent upon stockholder approval of a restated certificate of incorporation. Approval of that would increase the number of authorized shares of common stock from 200 million to 800 million. According […]
Ypsomed partners with CamDiab on smartphone-based automated insulin delivery
Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app. The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first […]
How the hospital may become a new market for CGMs
Following a breakthrough nod for Dexcom, CGMs may become a key part of hospital care. As the early stages of the COVID-19 pandemic required action in many forms, continuous glucose monitors became an unexpected part of hospital care. The FDA issued temporary guidance in April 2020 allowing for increased remote monitoring of hospital patients to […]
Diabetes tech is off to a hot start in 2022
Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Dexcom wins CE mark for next-gen G7 CGM, will begin European launch within weeks
Dexcom (Nasdaq:DXCM) announced today that it received CE mark approval in Europe for its G7 continuous glucose monitoring (CGM) system. The San Diego–based company has also submitted for an FDA 510(k) for G7 and awaits clearance in the U.S. Dexcom designed its next-generation CGM offering as an all-in-one wearable system. It warms up in 30 […]
Dexcom wins FDA breakthrough nod for use of its CGM in hospitals
Dexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in a hospital setting. The FDA early in the COVID-19 pandemic issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included continuous glucose monitors. “What started as a […]